Načítá se...
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic mali...
Uloženo v:
| Vydáno v: | J Blood Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5015873/ https://ncbi.nlm.nih.gov/pubmed/27621679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S70716 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|